title: A new predictive scoring system including shock index for unruptured tubal pregnancy patients.
abstract: OBJECTIVE
  Shock index (SI) and predictive score grading system including it for predicting medical treatment failure of tubal pregnancies have been studied.
  
  
  METHODS
  Eighty-eight patients were diagnosed as nonruptured tubal pregnancies. Shock index was calculated as the ratio of heart rate to systolic arterial pressure. A predictive score was used based on four parameters including initial level of beta-human chorionic gonadotropin (betahCG), aspect of the image on ultrasound, size of the ectopic mass and shock index value at admission.
  
  
  RESULTS
  Forty patients have undergone to surgery because of tubal gestational sac size > or =4 cm and/or presence of fetal heart activity. Nineteen patients were managed expectantly. Twenty-four patients received single dose methotrexate (MTX) and five patients received second dose MTX. Success rate for single dose MTX therapy was 72% (21/29). The cut-off shock index value for tubal rupture was 0.77 with 89% sensitivity and 61% specifity.
  
  
  CONCLUSIONS
  In this study, we demonstrated that tubal pregnancy patients who were managed with nonsurgical measures at admission and who had SI values lower than 0.77 and predictive score grades greater and equal to 6.5 did not experience tubal rupture and did not need surgical intervention during nonsurgical management.
authors.affiliation: Zekai Tahir Burak Women's Health and Research Hospital, Department of Infertility and Reproductive Medicine, Gn. Dr.Tevfik Saglam Cad. Emlakbankasi Evleri C3/32 Etlik, Ankara, Turkey. kralytmer@yahoo.com
authors.forename: Serkan
authors.initials: S
authors.lastname: Kahyaoglu
authors.forename: Inci
authors.initials: I
authors.lastname: Turgay
authors.forename: Muhammed
authors.initials: M
authors.lastname: Gocmen
authors.forename: Necdet
authors.initials: N
authors.lastname: Sut
authors.forename: Sertac
authors.initials: S
authors.lastname: Batioglu
mesh_terms: D000020:Abortifacient Agents, Nonsteroidal / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D001794:Blood Pressure; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000097:blood; D015331:Cohort Studies; D005260:Female; D006339:Heart Rate; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D011237:Predictive Value of Tests; D011247:Pregnancy; D011274:Pregnancy, Tubal / Q000097:blood / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D011446:Prospective Studies; D012372:ROC Curve; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D012769:Shock / Q000175:diagnosis* / Q000503:physiopathology; D014463:Ultrasonography
chemical_list: D000020:Abortifacient Agents, Nonsteroidal; D018997:Chorionic Gonadotropin, beta Subunit, Human; D008727:Methotrexate